To our knowledge, we are the first to report evidence that concurrent treatments of EGFR and autophagy inhibitors can significantly enhance the limited efficacy of EGFR inhibitors in human bladder cancer cells in vitro. Here, EGFR is linked to urinary bladder cancer.